Renalytix PLC - London-based diagnostics company focused on the management and testing of kidney disease through its KidneyIntelX platform - Chief Business Officer Howard Doran has been appointed as president, effective April 30. He replaces Thomas McLain, who is stepping down as president on the same date after serving in the role since July 2019. Doran has been business chief since September last year.
Chief Executive Officer James McCullough comments: "We thank Tom for his many accomplishments in helping Renalytix achieve the tri-fecta of broad insurance coverage, [US Food & Drug Administration] regulatory approval and real-world outcomes evidence that now positions KidneyIntelX for commercial adoption. Howard assumes the position of President to lead the global sales effort having now built our sales team from individuals with leading industry sales track records."
Current stock price: 29.20 pence, down 2.7%
12-month change: down 69%
By Greg Rosenvinge, Alliance News senior reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Renalytix Plc (RENX)